All Posts
JACC Scientific Statement | Remote monitoring for heart failure management at home
7 Jun, 2023 | 14:00h | UTC
Commentary on Twitter
New #JACC Scientific Statement spanning remote monitoring to integrated mgmt of #HeartFailure.
Updates in physiology of congestion, monitoring signals, & #DigitalHealth tech will support clinical teams to connect circles of care/self-care of #HF at home! https://t.co/TyaXT1P1hg pic.twitter.com/0u5STreIDQ
— JACC Journals (@JACCJournals) June 6, 2023
AAOS Appropriate Use Criteria | Prevention of surgical site infections after major extremity trauma
7 Jun, 2023 | 13:58h | UTCRelated:
Global guidelines on the prevention of surgical site infection – World Health Organization
AAOS Guideline: Prevention of surgical site infections after major extremity trauma.
Magnetic resonance imaging to evaluate kidney structure, function, and pathology: moving towards clinical application
7 Jun, 2023 | 13:57h | UTC
RCT | Atezolizumab and cabozantinib combo fails to outperform cabozantinib alone in renal cell carcinoma
7 Jun, 2023 | 13:54h | UTCAtezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial – The Lancet (free registration required)
Commentary from the author on Twitter (thread – click for more)
1/ Results from #CONTACT03 are out both @ASCO #ASCO23 and @TheLancet . The 1⃣st phase 3 trial to assess the efficacy of rechallenge with anti-PDL1 in ANY cancer type.
Kudos to @montypal, SC members, @roche, our patients, = for this phenomenal job. https://t.co/p7hYD4snXA pic.twitter.com/CXk1vqfB26— Toni Choueiri, MD (@DrChoueiri) June 5, 2023
M-A | Advance care planning for frail elderly: are we missing a golden opportunity?
7 Jun, 2023 | 13:53h | UTC
Exploratory Analysis of a RCT | Low-dose colchicine linked to reduced incidence of knee and hip replacements
7 Jun, 2023 | 13:50h | UTCAssociation of Low-Dose Colchicine With Incidence of Knee and Hip Replacements: Exploratory Analyses From a Randomized, Controlled, Double-Blind Trial – Annals of Internal Medicine (link to abstract – $ for full-text)
News Release: Low dose colchicine associated with lower incidence of total knee and hip replacements – American College of Physicians
Cohort Study | Coronary artery calcium score superior to polygenic score for CHD risk prediction
7 Jun, 2023 | 13:51h | UTCCoronary Artery Calcium Score and Polygenic Risk Score for the Prediction of Coronary Heart Disease Events – JAMA (link to abstract – $ for full-text)
News Release: CT scan best at predicting heart disease risk in middle age: Scan beats genetics to gauge risk – Northwestern University
Practice Guidance | Management of patients with differing heart failure phenotypes
7 Jun, 2023 | 13:45h | UTC
Review | Erythrocyte sedimentation rate and C-reactive protein in the ED
7 Jun, 2023 | 13:47h | UTCErythrocyte Sedimentation Rate and C-Reactive Protein in the ED – emDocs
Guideline | Managing chemotherapy-induced nausea and vomiting in pediatric cancer
7 Jun, 2023 | 13:43h | UTC
RCT | Adding dalpiciclib to standard letrozole or anastrozole treatment outperforms placebo in HR+, HER2- advanced breast cancer
7 Jun, 2023 | 13:44h | UTCDalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Dalpiciclib Combo Improves PFS Vs Placebo in HER2– Advanced Breast Cancer – Cancer Network
Guideline Series | Prevention and management of diabetes-related foot disease
7 Jun, 2023 | 13:41h | UTCDefinitions and criteria for diabetes-related foot disease (IWGDF 2023 update)
Guidelines on the classification of foot ulcers in people with diabetes (IWGDF 2023 update)
Guidelines on offloading foot ulcers in persons with diabetes (IWGDF 2023 update)
M-A | Effects of physical exercise on physical function in older adults in residential care
7 Jun, 2023 | 13:39h | UTCInvited commentary: Is there enough evidence to prescribe exercise to older adults living in residential care? – The Lancet Health Longevity
RCT | Immediate vs. delayed sequential bilateral cataract surgery: non-inferior in safety, higher cost-effectiveness
6 Jun, 2023 | 14:41h | UTCSafety, effectiveness, and cost-effectiveness of immediate versus delayed sequential bilateral cataract surgery in the Netherlands (BICAT-NL study): a multicentre, non-inferiority, randomised controlled trial – The Lancet (link to abstract – $ for full-text)
News Release: Cataract surgery: two-sided treatment better than one-by-one approach – Maastricht University
RCT | Tirzepatide outperforms insulin glargine in HbA1c reduction and weight loss in type 2 diabetes
6 Jun, 2023 | 14:39h | UTC
Commentary on Twitter
The SURPASS-AP-Combo trial shows that addition of #tirzepatide as 2L or 3L therapy is non-inferior & superior to insulin glargine for glycemic outcomes at 40 weeks in an Asia-Pacific (mostly Chinese) population w/ type 2 #diabetes. https://t.co/RDh2WSJ1wZ pic.twitter.com/nm6pPpVdxH
— Nature Medicine (@NatureMedicine) June 2, 2023
Review | How to understand the 95% confidence interval around the relative risk, odds ratio, and hazard ratio
6 Jun, 2023 | 14:37h | UTC
RCT | Perioperative pembrolizumab improves pathological outcomes, event-free survival in early-stage NSCLC
6 Jun, 2023 | 14:36h | UTCPerioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Presented at #ASCO23: In the KEYNOTE-671 trial, pts with resectable lung cancer were assigned to neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo. Two-year event-free survival was 62.4% with pembrolizumab & 40.6% with placebo.
— NEJM (@NEJM) June 3, 2023
RCT | Tirofiban results in greater likelihood of excellent outcome vs. aspirin in stroke without large vessel occlusion
6 Jun, 2023 | 14:33h | UTCTirofiban for Stroke without Large or Medium-Sized Vessel Occlusion – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Tirofiban for Stroke Without Large or Medium Vessel Occlusion – American College of Cardiology
Commentary on Twitter
Original Article: Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion (RESCUE BT2) https://t.co/Ul2kfAt9yX
Editorial: Expanding Treatment for Acute Ischemic Stroke beyond Revascularization: https://t.co/G8SAWnGJhS pic.twitter.com/21n0x4YqvK
— NEJM (@NEJM) June 1, 2023
SSAI Guideline | New-onset atrial fibrillation in critically ill adult patients
6 Jun, 2023 | 14:31h | UTC
Position Paper | Continuous electroencephalography in the intensive care unit
6 Jun, 2023 | 14:29h | UTC
Adrenaline auto-injector prescription for patients at risk of anaphylaxis: BSACI guidance for primary care
6 Jun, 2023 | 14:28h | UTC
Podcast | Insulin, type 2 diabetes, and hypoglycemia
6 Jun, 2023 | 14:25h | UTC#397: Insulin, Type 2 Diabetes, Fanny Packs, and Hypoglycemia with Dr. Jeff Colburn – The Curbsiders
Podcast | Hypopigmented and depigmented skin lesions in pediatrics
6 Jun, 2023 | 14:24h | UTC#84: Hypopigmented & Depigmented Skin Lesions: An En-LIGHT-ening Review – The Cribsiders
Podcast | Ascend your understanding of pelvic inflammatory disease
6 Jun, 2023 | 14:23h | UTC#83: Ascend Your Understanding of Pelvic Inflammatory Disease (PID) – The Cribsiders
Brief Review | What BP target is appropriate for pregnant patients with mild chronic hypertension?
6 Jun, 2023 | 14:20h | UTC